PMGC Holdings Inc. ELAB
Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026
PMGC Holdings Inc. (ELAB) is a healthcare company listed in the US with a market value of about $1M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$13M, a net margin of -275.7%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -76%.
About PMGC
PMGC is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. Revenue went from $766277 in 2022 to $590084 in 2025, a decline of about 8.3% a year. It was profitable in 0 of the last 4 years in our data. Its share count rose by 25027% over three years (dilution for shareholders). It spends 25% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $5M | $590084 | — | $2M | $766277 |
| Net income | -$13M | -$8M | -$6M | -$4M | -$2M |
| Free cash flow | -$10M | -$6M | -$5M | -$5M | — |
| EPS (diluted) | $-16.33 | $-9.56 | $-105.99 | $-1176.45 | $-555.87 |
| Net margin | -275.7% | -1313.0% | — | -251.2% | -234.9% |
| ROIC | — | -64.1% | — | -62.4% | -100.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does PMGC pay a dividend?
Not currently.
Is PMGC a good stock to buy?
We do not give buy or sell advice. PMGC scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.